XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details)

Subsequent Events (Details) $ / shares in Units, $ in Thousands							1 Months Ended	3 Months Ended
	Apr. 29, 2024 USD ($)	Apr. 23, 2024 USD ($)	Apr. 03, 2024 Right $ / shares	Feb. 27, 2024 USD ($)	Oct. 30, 2023 USD ($)	Mar. 22, 2021 USD ($)	Apr. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)
Subsequent Event
Payments of consideration under RPAs, AAAs and CPPAs								$ 15,000	$ 9,600
Revenue from contracts with customers								1,000
Kinnate \| Exarafenib and related IP \| Disposed of by Sale, Not Discontinued Operations
Subsequent Event
Cash consideration received				$ 500
Contingent consideration to be received upon achievement of specified milestones				$ 30,500
Viracta \| Royalty Purchase Agreement
Subsequent Event
Amount of milestone payments earned under agreement					$ 5,000
Payments of consideration under RPAs, AAAs and CPPAs						$ 13,500
Rezolute \| License Agreement
Subsequent Event
Revenue from contracts with customers								$ 0	$ 0
Subsequent Event \| CVR Agreement \| Exarafenib and related IP
Subsequent Event
Percentage of further net proceeds from transaction			100.00%
Percentage of net proceeds from any license or other disposition			85.00%
Subsequent Event \| Viracta \| Royalty Purchase Agreement
Subsequent Event
Amount of milestone payments earned under agreement		$ 9,000
Subsequent Event \| Dare \| Royalty Purchase Agreement
Subsequent Event
Payments of consideration under RPAs, AAAs and CPPAs	$ 22,000
Percentage of remaining royalties	100.00%
Subsequent Event \| Dare \| Royalty Purchase Agreement \| OVAPRENE and Sildenafil Cream \| Upon achievement of a pre-specified return threshold
Subsequent Event
Percentage of royalty which will decrease	3.60%
Subsequent Event \| Dare \| Royalty Purchase Agreement \| OVAPRENE
Subsequent Event
Royalties entity has right to receive (as a percent)	4.00%
Subsequent Event \| Dare \| Royalty Purchase Agreement \| OVAPRENE \| Upon achievement of a pre-specified return threshold
Subsequent Event
Royalties entity has right to receive (as a percent)	2.50%
Subsequent Event \| Dare \| Royalty Purchase Agreement \| Sildenafil Cream
Subsequent Event
Royalties entity has right to receive (as a percent)	2.00%
Subsequent Event \| Dare \| Royalty Purchase Agreement \| Sildenafil Cream \| Upon achievement of a pre-specified return threshold
Subsequent Event
Royalties entity has right to receive (as a percent)	1.25%
Subsequent Event \| Rezolute \| License Agreement
Subsequent Event
Revenue from contracts with customers							$ 5,000
Subsequent Event \| Kinnate
Subsequent Event
Cash amount of consideration per outstanding share (in dollars per share) \| $ / shares			$ 2.5879
Number of non-transferable contingent value rights for each acquiree share \| Right			1